A Phase 3 interventional study of Inclisiran and Placebo in Familial Hypercholesterolemia - Heterozygous, sponsored by Novartis Pharmaceuticals. Completed at 59 sites in 26 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Hyperlipoproteinemia Type II by Novartis — 4 open to participants now, 4 under way, 3 of them phase 3. Hyperlipoproteinemia Type II · Novartis.
Among the 11 studies in Hyperlipoproteinemia Type II by Novartis, this one is the only one that started in 2021, is one of 5 in phase 3, and was the 5th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →4 of the 11 studies in Hyperlipoproteinemia Type II by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18–99
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 20 more countries
Ages 6–11
Novartis Pharmaceuticals · Sites in United States, Argentina, Brazil and 23 more countries
Ages 2–100
By country, each count listing its studies:
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 141 is close to the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 113 across the 8 interventional studies, 5,995 across the 3 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Hyperlipoproteinemia Type II by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C).
This was a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) on stable standard of care background lipid-lowering therapy. The primary objective was to demonstrate superiority of inclisiran compared to placebo in reducing LDL-C (percent change) at Day 330.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
Drug: Inclisiran
Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
Drug: Placebo
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
Also known as: KJX839
Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Also known as: Saline solution
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)
Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)
Time frame: Baseline and Day 330
Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)
Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330
Time frame: Baseline, after Day 90 up to Day 330
Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1)
Absolute change in LDL-C from baseline to Day 330.
Time frame: Baseline and Day 330
Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1)
Percentage change in apolipoprotein B (Apo B) from baseline to Day 330.
Time frame: Baseline and Day 330
Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1)
Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to Day 330.
Time frame: Baseline and Day 330
Percent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1)
Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to Day 330.
Time frame: Baseline and Day 330
Percent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1)
Percentage change in total cholesterol from baseline to Day 330.
Time frame: Baseline and Day 330
Percent Change in LDL-C From Baseline up to Day 720
Percentage change in LDL-C from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in LDL-C From Baseline up to Day 720
Absolute change in LDL-C from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Apo B From Baseline up to Day 720
Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Apo B From Baseline up to Day 720
Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Lp(a) From Baseline up to Day 720
Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Lp(a) From Baseline up to Day 720
Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Non-HDL-C From Baseline up to Day 720
Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Non-HDL-C From Baseline up to Day 720
Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Total Cholesterol From Baseline up to Day 720
Percentage change in total cholesterol from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Total Cholesterol From Baseline up to Day 720
Absolute change in total cholesterol from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Triglycerides From Baseline up to Day 720
Percentage change in triglycerides from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Triglycerides From Baseline up to Day 720
Absolute change in triglycerides from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in HDL-C From Baseline up to Day 720
Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in HDL-C From Baseline up to Day 720
Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in VLDL-C From Baseline up to Day 720
Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolut Change in VLDL-C From Baseline up to Day 720
Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in Apo A1 From Baseline up to Day 720
Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolute Change in Apo A1 From Baseline up to Day 720
Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Percent Change in PCSK9 From Baseline up to Day 720
Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
Absolut Change in PCSK9 From Baseline up to Day 720
Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
Time frame: Baseline, up to Day 720
141 participants were randomized in 26 countries and 51 study centers:Argentina (1), Brazil (3), Canada (1), Czech Republic (2), France (3), Germany (2), Greece (1), Hungary (1), Israel (2), Italy (4), Jordan (1), Lebanon (1), Malaysia (1), Netherlands (2), Norway (1), Poland (2), Russian Federation (2), Slovakia (1), Slovenia (1), South Africa (3), Spain (4), Switzerland (1), Taiwan (1), Turkey (4), United Kingdom (1), and United States of America (5).
| Milestone | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Started | 93 | 48 | 0 |
| Completed | 91 | 48 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Participant/guardian decision | 1 | 0 | 0 |
| Milestone | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Started | 0 | 0 | 139 |
| Completed | 0 | 0 | 139 |
| Not completed | 0 | 0 | 0 |
Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)
| percent change in LDL-C | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) | -27.14 (-32.04 to -22.24) | 1.40 (-3.97 to 6.78) |
Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330
| Time-adjusted percent change in LDL-C | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1) | -26.04 (-30.11 to -21.98) | 3.26 (-2.37 to 8.89) |
Absolute change in LDL-C from baseline to Day 330.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1) | -50.54 (-59.22 to -41.86) | -0.55 (-10.48 to 9.38) |
Percentage change in apolipoprotein B (Apo B) from baseline to Day 330.
| Percent change in Apo B | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1) | -21.46 (-25.59 to -17.33) | 4.24 (-0.07 to 8.56) |
Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to Day 330.
| Percent change in Lp(a) | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1) | -5.04 (-14.21 to 4.13) | 1.14 (-5.48 to 7.77) |
Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to Day 330.
| Percent change in non-HDL-C | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Percent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1) | -25.04 (-29.68 to -20.41) | 1.76 (-3.25 to 6.77) |
Percentage change in total cholesterol from baseline to Day 330.
| Percent change in total cholesterol | Part 1- Inclisiran | Part 1 - Placebo |
|---|---|---|
| Percent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1) | -18.72 (-22.48 to -14.96) | 0.48 (-3.46 to 4.42) |
Percentage change in LDL-C from baseline to each assessment time up to Day 720.
| Percent change in LDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 90 | -23.9 ± 22.14 | -0.1 ± 20.16 | — |
| DAY 150 | -32.5 ± 21.47 | 6.4 ± 28.83 | — |
| DAY 270 | -19.0 ± 28.31 | 2.1 ± 22.44 | — |
| DAY 330 | -27.8 ± 22.95 | 1.5 ± 20.59 | — |
| DAY 360 | -26.1 ± 22.71 | 1.5 ± 30.56 | — |
| DAY 450 | — | — | -24.5 ± 26.45 |
| DAY 510 | — | — | -32.5 ± 22.80 |
| DAY 630 | — | — | -26.5 ± 24.33 |
| Day 720 (study completion) | — | — | -33.7 ± 23.98 |
Absolute change in LDL-C from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 90 | -45.4 ± 45.26 | -3.0 ± 35.02 | — |
| DAY 150 | -61.0 ± 45.84 | 6.6 ± 46.22 | — |
| DAY 270 | -38.4 ± 55.77 | 1.0 ± 36.92 | — |
| DAY 330 | -51.9 ± 45.47 | -0.3 ± 38.04 | — |
| DAY 360 | -49.0 ± 44.49 | -2.9 ± 51.74 | — |
| DAY 450 | — | — | -46.3 ± 52.51 |
| DAY 510 | — | — | -60.8 ± 48.88 |
| DAY 630 | — | — | -50.9 ± 50.30 |
| Day 720 (study completion) | — | — | -64.1 ± 53.91 |
Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
| Percent change in Apo B | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -25.1 ± 18.18 | 2.2 ± 20.77 | — |
| DAY 330 | -21.9 ± 19.51 | 3.9 ± 18.13 | — |
| DAY 360 | -19.3 ± 21.36 | 1.7 ± 22.70 | — |
| DAY 510 | — | — | -24.5 ± 21.77 |
| Day 720 (study completion) | — | — | -25.7 ± 21.71 |
Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -33.3 ± 28.20 | 0.0 ± 27.38 | — |
| DAY 330 | -29.2 ± 28.04 | 2.9 ± 23.47 | — |
| DAY 360 | -26.1 ± 29.59 | -0.6 ± 28.72 | — |
| DAY 510 | — | — | -33.5 ± 32.13 |
| Day 720 (study completion) | — | — | -35.4 ± 33.83 |
Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
| Percent change in Lp(a) | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -13.4 ± 22.60 | 5.4 ± 23.96 | — |
| DAY 330 | -7.2 ± 30.80 | 1.1 ± 24.25 | — |
| DAY 360 | -9.3 ± 28.44 | 3.6 ± 23.27 | — |
| DAY 510 | — | — | -13.3 ± 28.81 |
| Day 720 (study completion) | — | — | -4.2 ± 163.74 |
Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
| nmol/L | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -12.5 ± 34.73 | 3.2 ± 20.67 | — |
| DAY 330 | -9.5 ± 33.81 | 5.3 ± 21.55 | — |
| DAY 360 | -10.2 ± 31.16 | 4.4 ± 22.99 | — |
| DAY 510 | — | — | -10.1 ± 34.98 |
| Day 720 (study completion) | — | — | -9.0 ± 50.08 |
Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
| Percent change in non-HDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -29.0 ± 20.15 | 5.1 ± 24.85 | — |
| DAY 330 | -25.7 ± 21.69 | 1.8 ± 19.43 | — |
| DAY 360 | -24.0 ± 21.74 | 1.2 ± 27.43 | — |
| DAY 510 | — | — | -29.9 ± 21.60 |
| Day 720 (study completion) | — | — | -31.0 ± 23.04 |
Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -60.2 ± 47.41 | 5.7 ± 47.61 | — |
| DAY 330 | -52.6 ± 46.93 | 0.5 ± 39.20 | — |
| DAY 360 | -49.7 ± 46.30 | -3.0 ± 52.75 | — |
| DAY 510 | — | — | -62.0 ± 51.09 |
| Day 720 (study completion) | — | — | -65.1 ± 56.16 |
Percentage change in total cholesterol from baseline to each assessment time up to Day 720.
| Percent change in total cholesterol | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -22.6 ± 15.77 | 4.4 ± 20.49 | — |
| DAY 330 | -19.2 ± 17.77 | 0.6 ± 15.46 | — |
| DAY 360 | -18.5 ± 17.18 | 0.6 ± 21.81 | — |
| DAY 510 | — | — | -23.0 ± 17.50 |
| Day 720 (study completion) | — | — | -23.7 ± 18.29 |
Absolute change in total cholesterol from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | -59.0 ± 47.79 | 6.6 ± 48.08 | — |
| DAY 330 | -49.4 ± 47.77 | -0.9 ± 38.48 | — |
| DAY 360 | -48.2 ± 47.06 | -3.1 ± 52.66 | — |
| DAY 510 | — | — | -59.6 ± 51.06 |
| Day 720 (study completion) | — | — | -62.3 ± 55.05 |
Percentage change in triglycerides from baseline to each assessment time up to Day 720.
| Percent change in triglycerides | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 16.2 ± 78.18 | 2.8 ± 37.44 | — |
| DAY 330 | 1.8 ± 38.39 | 9.7 ± 43.04 | — |
| DAY 360 | 1.7 ± 40.03 | 3.8 ± 35.76 | — |
| DAY 510 | — | — | 3.4 ± 43.08 |
| Day 720 (study completion) | — | — | 1.9 ± 41.84 |
Absolute change in triglycerides from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 6.9 ± 64.67 | -4.8 ± 31.53 | — |
| DAY 330 | -2.9 ± 35.01 | 3.5 ± 35.55 | — |
| DAY 360 | -3.1 ± 38.13 | -1.7 ± 28.47 | — |
| DAY 510 | — | — | -4.2 ± 34.70 |
| Day 720 (study completion) | — | — | -4.8 ± 36.21 |
Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
| Percent change in HDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 3.6 ± 18.88 | 3.6 ± 16.49 | — |
| DAY 330 | 7.4 ± 19.15 | -1.9 ± 16.15 | — |
| DAY 360 | 4.4 ± 19.54 | 0.9 ± 12.39 | — |
| DAY 510 | — | — | 6.6 ± 19.84 |
| Day 720 (study completion) | — | — | 7.4 ± 20.40 |
Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 1.2 ± 10.23 | 0.9 ± 8.07 | — |
| DAY 330 | 3.2 ± 9.57 | -1.4 ± 7.77 | — |
| DAY 360 | 1.5 ± 9.59 | -0.1 ± 6.23 | — |
| DAY 510 | — | — | 2.4 ± 9.32 |
| Day 720 (study completion) | — | — | 2.8 ± 9.75 |
Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
| Percent change in VLDL-C | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 11.8 ± 60.04 | 3.3 ± 38.25 | — |
| DAY 330 | 0.6 ± 39.00 | 10.0 ± 42.29 | — |
| DAY 360 | 1.0 ± 40.15 | 4.7 ± 35.65 | — |
| DAY 510 | — | — | 1.4 ± 41.13 |
| Day 720 (study completion) | — | — | 1.9 ± 42.20 |
Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 0.7 ± 10.02 | -0.9 ± 6.37 | — |
| DAY 330 | -0.7 ± 7.04 | 0.8 ± 7.07 | — |
| DAY 360 | -0.7 ± 7.63 | -0.2 ± 5.66 | — |
| DAY 510 | — | — | -1.2 ± 6.90 |
| Day 720 (study completion) | — | — | -1.0 ± 7.40 |
Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
| Percent change in Apo A1 | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 3.7 ± 15.40 | 0.4 ± 13.22 | — |
| DAY 330 | 5.2 ± 14.49 | -1.5 ± 10.58 | — |
| DAY 360 | 3.0 ± 15.12 | -1.5 ± 9.98 | — |
| DAY 510 | — | — | 6.3 ± 16.19 |
| Day 720 (study completion) | — | — | 4.9 ± 15.56 |
Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
| mg/dL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 150 | 3.3 ± 21.76 | 0.0 ± 17.72 | — |
| DAY 330 | 6.1 ± 21.16 | -2.8 ± 14.24 | — |
| DAY 360 | 2.7 ± 21.87 | -2.6 ± 13.89 | — |
| DAY 510 | — | — | 7.5 ± 22.24 |
| Day 720 (study completion) | — | — | 5.4 ± 21.61 |
Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
| Percent change in PCSK9 | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 90 | -67.8 ± 15.17 | 11.6 ± 46.61 | — |
| DAY 150 | -72.3 ± 11.37 | 3.8 ± 36.95 | — |
| DAY 330 | -72.9 ± 12.12 | 4.8 ± 34.50 | — |
| DAY 360 | -72.0 ± 10.47 | 11.7 ± 57.77 | — |
| DAY 510 | — | — | -74.3 ± 10.46 |
| Day 720 (study completion) | — | — | -71.6 ± 13.42 |
Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.
| ng/mL | Part 1- Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| DAY 90 | -259.6 ± 121.5 | 2.1 ± 223.16 | — |
| DAY 150 | -274.8 ± 116.2 | -27.7 ± 210.44 | — |
| DAY 330 | -278.2 ± 119.8 | -23.9 ± 210.85 | — |
| DAY 360 | -275.4 ± 117.2 | -9.1 ± 245.36 | — |
| DAY 510 | — | — | -288.1 ± 156.9 |
| Day 720 (study completion) | — | — | -279.5 ± 159.2 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 90 days post treatment or 30 days after last study visit, whichever was longer, up to a maximum duration of approximately 2 years.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - Inclisiran | 0/93 (0%) | 3/93 (3.2%) | 57/93 (61.3%) |
| Part 1 - Placebo | 0/48 (0%) | 1/48 (2.1%) | 29/48 (60.4%) |
| Part 2 - Inclisiran (Total) | 0/139 (0%) | 6/139 (4.3%) | 52/139 (37.4%) |
| Event | Part 1 - Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| Supraventricular tachycardiaCardiac disorders | 0/93 | 1/48 | 0/139 |
| Anaphylactic reactionImmune system disorders | 1/93 | 0/48 | 1/139 |
| Dengue feverInfections and infestations | 1/93 | 0/48 | 0/139 |
| Status migrainosusNervous system disorders | 1/93 | 0/48 | 0/139 |
| ConcussionInjury, poisoning and procedural complications | 0/93 | 0/48 | 1/139 |
| Blood creatine phosphokinase increasedInvestigations | 0/93 | 0/48 | 1/139 |
| SyncopeNervous system disorders | 0/93 | 0/48 | 1/139 |
| AnxietyPsychiatric disorders | 0/93 | 0/48 | 1/139 |
| Varicose veinVascular disorders | 0/93 | 0/48 | 1/139 |
| Event | Part 1 - Inclisiran | Part 1 - Placebo | Part 2 - Inclisiran (Total) |
|---|---|---|---|
| COVID-19Infections and infestations | 17/93 | 12/48 | 7/139 |
| NasopharyngitisInfections and infestations | 13/93 | 9/48 | 14/139 |
| HeadacheNervous system disorders | 12/93 | 3/48 | 6/139 |
| InfluenzaInfections and infestations | 10/93 | 6/48 | 11/139 |
| Injection site reactionGeneral disorders | 8/93 | 1/48 | 5/139 |
| Upper respiratory tract infectionInfections and infestations | 6/93 | 2/48 | 4/139 |
| Influenza like illnessGeneral disorders | 4/93 | 3/48 | 2/139 |
| VomitingGastrointestinal disorders | 5/93 | 1/48 | 0/139 |
| SyncopeNervous system disorders | 5/93 | 0/48 | 1/139 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/93 | 2/48 | 6/139 |
Baseline Characteristics are based on all randomized participants
| Age, Categorical(Participants) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| <=18 years | 93 | 48 | 141 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| Mean | 15.2 ± 2.02 | 14.9 ± 1.80 | 15.1 ± 1.94 |
| Sex: Female, Male(Participants) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| Female | 51 | 24 | 75 |
| Male | 42 | 24 | 66 |
| Race/Ethnicity, Customized(Participants) | Part 1- Inclisiran | Part 1 - Placebo | Total |
|---|---|---|---|
| Asian | 4 | 0 | 4 |
| Black or African American | 5 | 0 | 5 |
| Other | 4 | 0 | 4 |
| White | 80 | 48 | 128 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Jan 2021 to primary completion in Nov 2023, 33 months.
Results were first posted in Jun 2025, 1 year 7 months after primary completion. A results delay was requested in Jun 2024.
Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 33 months is above that.
Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran
Hyperlipoproteinemia Type II →